Maria Roxana Biricioiu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Maria Roxana Biricioiu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alina Diana Zamfir
National Institute for Research and Development in Electrochemistry and Condensed Matter
6 shared publications - Mirela Sarbu
National Institute for Research and Development in Electrochemistry and Condensed Matter, 300224 Timisoara, Romania
6 shared publications - Raluca Ica
Department of Condensed Matter, National Institute for Research and Development in Electrochemistry and Condensed Matter, 300224 Timisoara, Romania
6 shared publications - Dragana Fabris
Department of Medical Chemistry, Biochemistry and Clinical Chemistry, School of Medicine, University of Zagreb, Zagreb, Croatia
2 shared publications - Liana Dehelean
Neuroscience Department, Faculty of Medicine, “Victor Babes” University of Medicine and Pharmacy, 300041 Timisoara, Romania
2 shared publications - Svjetlana Kalanj-Bognar
Department of Chemistry and Biochemistry, School of Medicine, University of Zagreb, Zagreb, Croatia
2 shared publications
Latest Publications
- Open Access
- 22 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2854
Glycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches
This narrative literature review synthesizes recent evidence on glycosphingolipid (GSL) dysregulation in dementia, emphasizing discoveries enabled by mass spectrometry (MS) and systems biology. Focusing on the research published within the last decade, we selected studies that are relevant to GSL alterations in dementia and notable for their methodological advances. The findings were conceptually integrated to emphasize key molecular, analytical, and systems-level aspects across the major dementia types. The results from MS-based glycolipidomics in Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease dementia, and Huntington’s disease consistently indicate altered GSL metabolism and shared molecular vulnerabilities in neuronal lipid regulation. At the same time, distinct GSL signatures differentiate individual dementias, reflecting the disease-specific mechanisms of neurodegeneration. The literature also reveals that recent advances in high-resolution MS and integrative analytical workflows have shifted GSL research from descriptive to mechanistic, facilitating the detailed mapping of species linked to neuroinflammation, protein aggregation, and synaptic dysfunction. Systems-level analyses combining MS data with other omics approaches increasingly depict GSLs as active regulators of neuronal function rather than inert membrane components. At the same time, emerging trends position GSLs as promising early biomarkers and potential therapeutic targets, while the growing use of artificial intelligence in MS data analysis is accelerating the detection of their subtle patterns, improving cross-disease comparisons. Together, these results reinforce the major role of MS-based platforms in discovering dementia-associated GSLs, identifying therapeutic targets, and influencing future strategies for diagnosis and treatment.
- 22 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2854
Open AccessGlycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches
This narrative literature review synthesizes recent evidence on glycosphingolipid (GSL) dysregulation in dementia, emphasizing discoveries enabled by mass spectrometry (MS) and systems biology. Focusing on the research published within the last decade, we selected studies that are relevant to GSL alterations in dementia and notable for their methodological advances. The findings were conceptually integrated to emphasize key molecular, analytical, and systems-level aspects across the major dementia types. The results from MS-based glycolipidomics in Alzheimer’s disease, dementia with Lewy bodies, frontotemporal dementia, Parkinson’s disease dementia, and Huntington’s disease consistently indicate altered GSL metabolism and shared molecular vulnerabilities in neuronal lipid regulation. At the same time, distinct GSL signatures differentiate individual dementias, reflecting the disease-specific mechanisms of neurodegeneration. The literature also reveals that recent advances in high-resolution MS and integrative analytical workflows have shifted GSL research from descriptive to mechanistic, facilitating the detailed mapping of species linked to neuroinflammation, protein aggregation, and synaptic dysfunction. Systems-level analyses combining MS data with other omics approaches increasingly depict GSLs as active regulators of neuronal function rather than inert membrane components. At the same time, emerging trends position GSLs as promising early biomarkers and potential therapeutic targets, while the growing use of artificial intelligence in MS data analysis is accelerating the detection of their subtle patterns, improving cross-disease comparisons. Together, these results reinforce the major role of MS-based platforms in discovering dementia-associated GSLs, identifying therapeutic targets, and influencing future strategies for diagnosis and treatment.
- Open Access
- 15 October 2025
- Published by MDPI AG in Preprints.org
Glycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches
This review synthesizes the current evidence on glycolipid dysregulation in dementia, with a focus on the data generated by mass spectrometry (MS) and systems biology approaches. Glycolipids, key regulators of neuronal function and integrity, have emerged as important players in neurodegenerative processes. In this context, we ex-amine here their altered expression reported in major forms of dementia, including Alzheimer’s disease, frontotemporal dementia, dementia with Lewy body, Parkinson's disease dementia, Huntington’s disease, and mixed dementia. By comparing these conditions, we identified molecular signatures that appear broadly conserved, suggesting common pathways of neuronal vulnerability, while also outlining disease-specific changes that may cause the observed clinical diversity. A special consideration is given to methodological advances, particularly the development and application of high performance MS in glyolipidomics and integrative analytical workflows, which have significantly expanded our understanding of lipid-mediated mechanisms in the diseased brain. Situating these findings within the context of dementia research, we further discuss here how glycolipid biology intersects with protein aggregation, neuroinflammation, and synaptic dysfunction. The results assessed here highlight the major role of MS-based platforms in discovery of glycolipids associated to dementia pathogenesis and at the same time of species with potential biomarker role and/or as novel targets for therapeutic intervention. This review, thus, provides an integrative perspective on glycolipid research by modern MS and allied techniques, emphasizing its potential to influence future strategies for diagnosis and treatment of dementia.
- 15 October 2025
- Published by MDPI AG in Preprints.org
Open AccessGlycosphingolipids in Dementia: Insights from Mass Spectrometry and Systems Biology Approaches
This review synthesizes the current evidence on glycolipid dysregulation in dementia, with a focus on the data generated by mass spectrometry (MS) and systems biology approaches. Glycolipids, key regulators of neuronal function and integrity, have emerged as important players in neurodegenerative processes. In this context, we ex-amine here their altered expression reported in major forms of dementia, including Alzheimer’s disease, frontotemporal dementia, dementia with Lewy body, Parkinson's disease dementia, Huntington’s disease, and mixed dementia. By comparing these conditions, we identified molecular signatures that appear broadly conserved, suggesting common pathways of neuronal vulnerability, while also outlining disease-specific changes that may cause the observed clinical diversity. A special consideration is given to methodological advances, particularly the development and application of high performance MS in glyolipidomics and integrative analytical workflows, which have significantly expanded our understanding of lipid-mediated mechanisms in the diseased brain. Situating these findings within the context of dementia research, we further discuss here how glycolipid biology intersects with protein aggregation, neuroinflammation, and synaptic dysfunction. The results assessed here highlight the major role of MS-based platforms in discovery of glycolipids associated to dementia pathogenesis and at the same time of species with potential biomarker role and/or as novel targets for therapeutic intervention. This review, thus, provides an integrative perspective on glycolipid research by modern MS and allied techniques, emphasizing its potential to influence future strategies for diagnosis and treatment of dementia.
- Open Access
- 29 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8433
Novel Application of Ion Mobility Mass Spectrometry Reveals Complex Ganglioside Landscape in Diffuse Astrocytoma Peritumoral Regions
Diffuse astrocytoma is a primary brain tumor known for its gradual and diffuse infiltration into the surrounding brain tissue. Given this characteristic, the investigation of the peritumoral region holds potential biological and clinical relevance. In this study, ion mobility spectrometry mass spectrometry (IMS MS) was optimized and applied for the first time for the analysis of gangliosides present in the peritumoral tissue of diffuse astrocytoma. Ganglioside profiling and structural characterization were conducted using high-resolution nanoelectrospray ionization (nanoESI) IMS MS, along with tandem mass spectrometry (MS/MS) via low-energy collision-induced dissociation (CID) in the negative ion mode. Using IMS MS-based separation and screening, we observed a greater diversity of ganglioside species in the peritumoral tissue than previously reported. Notably, an elevated expression was detected for several species, including GT1(d18:1/18:0), GT1(d18:1/20:0), GM2(d18:1/16:2), GD1(d18:1/16:0), GD2(d18:1/20:0), Fuc-GT3(d18:1/24:4), and Fuc-GD1(d18:1/18:2). Although preliminary, these observations prompt consideration of whether these species could be implicated in processes such as microenvironmental modulation, tumor cell infiltration and invasion, maintenance of cellular interactions, or regulation of immune responses. Additionally, their potential utility as biomarkers may merit further exploration. In the subsequent phase of the study, structural analysis using IMS MS, CID tandem MS, and fragmentation data supported the identification of GT1b(d18:1/20:0) isomer in the peritumoral tissue. However, given the exploratory nature of the study and reliance on limited sampling, further investigation across broader sample sets is necessary to extend these findings.
- 29 August 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (17) , 8433
Open AccessNovel Application of Ion Mobility Mass Spectrometry Reveals Complex Ganglioside Landscape in Diffuse Astrocytoma Peritumoral Regions
Diffuse astrocytoma is a primary brain tumor known for its gradual and diffuse infiltration into the surrounding brain tissue. Given this characteristic, the investigation of the peritumoral region holds potential biological and clinical relevance. In this study, ion mobility spectrometry mass spectrometry (IMS MS) was optimized and applied for the first time for the analysis of gangliosides present in the peritumoral tissue of diffuse astrocytoma. Ganglioside profiling and structural characterization were conducted using high-resolution nanoelectrospray ionization (nanoESI) IMS MS, along with tandem mass spectrometry (MS/MS) via low-energy collision-induced dissociation (CID) in the negative ion mode. Using IMS MS-based separation and screening, we observed a greater diversity of ganglioside species in the peritumoral tissue than previously reported. Notably, an elevated expression was detected for several species, including GT1(d18:1/18:0), GT1(d18:1/20:0), GM2(d18:1/16:2), GD1(d18:1/16:0), GD2(d18:1/20:0), Fuc-GT3(d18:1/24:4), and Fuc-GD1(d18:1/18:2). Although preliminary, these observations prompt consideration of whether these species could be implicated in processes such as microenvironmental modulation, tumor cell infiltration and invasion, maintenance of cellular interactions, or regulation of immune responses. Additionally, their potential utility as biomarkers may merit further exploration. In the subsequent phase of the study, structural analysis using IMS MS, CID tandem MS, and fragmentation data supported the identification of GT1b(d18:1/20:0) isomer in the peritumoral tissue. However, given the exploratory nature of the study and reliance on limited sampling, further investigation across broader sample sets is necessary to extend these findings.
- Open Access
- 30 June 2025
- Published by MDPI AG in Preprints.org
Novel Application of Ion Mobility Mass Spectrometry Reveals Complex Ganglioside Landscape in Diffuse Astrocytoma Peritumoral Regions
Diffuse astrocytoma is a primary brain tumor characterized by an insidious infiltration of tumor cells into surrounding brain tissue. Considering this trait, investigation of the peritumoral region is of major biological and clinical importance. In this study, ion mobility mass spectrometry (IMS MS) was optimized and introduced for the first time in the analysis of gangliosides expressed in the peritumoral tissue of diffuse astrocytoma. Profiling and structural analysis of ganglioside species were performed by high-resolution nanoelectrospray ionization (nanoESI) IMS MS and tandem MS (MS/MS) by collision induced dissociation at low energies tuned in the negative ion mode. Through IMS MS separation and screening, we discovered that the diversity of gangliosides in peritumoral tissue is significantly larger than previously reported. We observed the high expression of GT1(d18:1/18:0), GT1(d18:1/20:0), GM2(d18:1/16:2), GD1(d18:1/16:0), GD2(d18:1/20:0), Fuc-GT3(d18:1/24:4), and Fuc-GD1(d18:1/18:2), which suggest that these species: a) are potential biomarkers; b) create a microenvironment favorable to the infiltration of the tumor cells; c) promote the invasion of diffuse astrocytoma cells; d) uphold cellular interactions and possibly influence immune responses.In the second phase, IMS MS, tandem MS, and fragmentation data confirmed the structure of GT1(d18:1/20:0), identifying GT1b as the only isomer present in peritumoral regions.
- 30 June 2025
- Published by MDPI AG in Preprints.org
Open AccessNovel Application of Ion Mobility Mass Spectrometry Reveals Complex Ganglioside Landscape in Diffuse Astrocytoma Peritumoral Regions
Diffuse astrocytoma is a primary brain tumor characterized by an insidious infiltration of tumor cells into surrounding brain tissue. Considering this trait, investigation of the peritumoral region is of major biological and clinical importance. In this study, ion mobility mass spectrometry (IMS MS) was optimized and introduced for the first time in the analysis of gangliosides expressed in the peritumoral tissue of diffuse astrocytoma. Profiling and structural analysis of ganglioside species were performed by high-resolution nanoelectrospray ionization (nanoESI) IMS MS and tandem MS (MS/MS) by collision induced dissociation at low energies tuned in the negative ion mode. Through IMS MS separation and screening, we discovered that the diversity of gangliosides in peritumoral tissue is significantly larger than previously reported. We observed the high expression of GT1(d18:1/18:0), GT1(d18:1/20:0), GM2(d18:1/16:2), GD1(d18:1/16:0), GD2(d18:1/20:0), Fuc-GT3(d18:1/24:4), and Fuc-GD1(d18:1/18:2), which suggest that these species: a) are potential biomarkers; b) create a microenvironment favorable to the infiltration of the tumor cells; c) promote the invasion of diffuse astrocytoma cells; d) uphold cellular interactions and possibly influence immune responses.In the second phase, IMS MS, tandem MS, and fragmentation data confirmed the structure of GT1(d18:1/20:0), identifying GT1b as the only isomer present in peritumoral regions.
- Open Access
- 22 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1335
Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers
Gangliosides are highly abundant in the human brain where they are involved in major biological events. In brain cancers, alterations of ganglioside pattern occur, some of which being correlated with neoplastic transformation, while others with tumor proliferation. Of all techniques, mass spectrometry (MS) has proven to be one of the most effective in gangliosidomics, due to its ability to characterize heterogeneous mixtures and discover species with biomarker value. This review highlights the most significant achievements of MS in the analysis of gangliosides in human brain cancers. The first part presents the latest state of MS development in the discovery of ganglioside markers in primary brain tumors, with a particular emphasis on the ion mobility separation (IMS) MS and its contribution to the elucidation of the gangliosidome associated with aggressive tumors. The second part is focused on MS of gangliosides in brain metastases, highlighting the ability of matrix-assisted laser desorption/ionization (MALDI)-MS, microfluidics-MS and tandem MS to decipher and structurally characterize species involved in the metastatic process. In the end, several conclusions and perspectives are presented, among which the need for development of reliable software and a user-friendly structural database as a search platform in brain tumor diagnostics.
- 22 January 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (2) , 1335
Open AccessAdvances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers
Gangliosides are highly abundant in the human brain where they are involved in major biological events. In brain cancers, alterations of ganglioside pattern occur, some of which being correlated with neoplastic transformation, while others with tumor proliferation. Of all techniques, mass spectrometry (MS) has proven to be one of the most effective in gangliosidomics, due to its ability to characterize heterogeneous mixtures and discover species with biomarker value. This review highlights the most significant achievements of MS in the analysis of gangliosides in human brain cancers. The first part presents the latest state of MS development in the discovery of ganglioside markers in primary brain tumors, with a particular emphasis on the ion mobility separation (IMS) MS and its contribution to the elucidation of the gangliosidome associated with aggressive tumors. The second part is focused on MS of gangliosides in brain metastases, highlighting the ability of matrix-assisted laser desorption/ionization (MALDI)-MS, microfluidics-MS and tandem MS to decipher and structurally characterize species involved in the metastatic process. In the end, several conclusions and perspectives are presented, among which the need for development of reliable software and a user-friendly structural database as a search platform in brain tumor diagnostics.
- Open Access
- 7 December 2023
- Published by MDPI AG in Preprints.org
Advances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers
Gangliosides are highly abundant in the human brain where they are involved in major biological events. In brain cancers, alterations of ganglioside pattern occur, some of which being correlated with the neoplastic transformation, while others with the tumor proliferation. Of all the techniques, mass spectrometry (MS) has proven to be one of the most effective in gangliosidomics, due to its ability to characterize heterogeneous mixtures and discover species with biomarker value. This review highlights the most significant achievements of MS in the analysis of gangliosides in human brain cancers. The first part presents the state-of-the-art in the MS development for discovery of ganglioside markers in primary brain tumors, with a particular emphasis on the ion mobility separation (IMS) MS and its contribution to the elucidation of the gangliosidome associated with aggressive tumors. The second part is focused on the MS of gangliosides in brain metastases, highlighting the ability of matrix-assisted laser desorption/ionization (MALDI)-MS, microfluidics-MS and tandem MS to decipher and structurally characterize species involved in the metastatic process. In the end, several conclusions and perspectives are presented, among which the need for development of a reliable software and a user-friendly structural database as a search platform in brain tumor diagnostics.
- 7 December 2023
- Published by MDPI AG in Preprints.org
Open AccessAdvances in Mass Spectrometry of Gangliosides Expressed in Brain Cancers
Gangliosides are highly abundant in the human brain where they are involved in major biological events. In brain cancers, alterations of ganglioside pattern occur, some of which being correlated with the neoplastic transformation, while others with the tumor proliferation. Of all the techniques, mass spectrometry (MS) has proven to be one of the most effective in gangliosidomics, due to its ability to characterize heterogeneous mixtures and discover species with biomarker value. This review highlights the most significant achievements of MS in the analysis of gangliosides in human brain cancers. The first part presents the state-of-the-art in the MS development for discovery of ganglioside markers in primary brain tumors, with a particular emphasis on the ion mobility separation (IMS) MS and its contribution to the elucidation of the gangliosidome associated with aggressive tumors. The second part is focused on the MS of gangliosides in brain metastases, highlighting the ability of matrix-assisted laser desorption/ionization (MALDI)-MS, microfluidics-MS and tandem MS to decipher and structurally characterize species involved in the metastatic process. In the end, several conclusions and perspectives are presented, among which the need for development of a reliable software and a user-friendly structural database as a search platform in brain tumor diagnostics.